摘要
目的：观察希罗达联合奥沙利铂（XELOX方案）治疗中晚期胃癌和结直肠癌的近期疗效和毒副反应。方法：回顾性分析86例应用希罗迭联合奥沙利铂治疗的中晚期胃癌和结直肠癌患者的临床资料，观察其近期临床疗效和毒副反应；治疗方案（XELOX方案）：奥沙利铂130mg／m2静滴2h，第1天；希罗达2000mg／m2，分早晚两次餐后口服用温开水送服，第1～14d，每3周重复。结果：86例中晚期消化道恶性肿瘤患者总有效率52．3％，肿瘤控制率（CR＋PR＋SD）74．4％；大部分病人主观感觉症状减轻，生活质量提高，毒副反应轻微，鲍太多数患者可以耐受。结论：希罗这联合奥沙利铂作为一线方案治疗中晚期胃癌和结直肠癌近期疗效确切，并显著改善临床症状，提高生存质量，毒副反应低，且可耐受。
Objective The purpose of this study was to evaluate the near efficacy and toxicity of oxaliplatin plus eapecitabine（XELOX） in the treatment of advanced gastric and colorectal cancer, short--term clinical efficacy and observed toxicity. Methods We retrospect 86 cases who was diagnosed with advanced gastric and colorectal cancer and analysis the clinical document, evaluate the near efficacy and toxicity. The cases was administrated with oxaliplatin plus xeloda （XELOX） （ oxaliplatin 85 mg/m2 infused in Intravenously drip for 2h day 1 ; Xeloda taken orally 2000 mg/m2 day 1 to 14, repeated 21 days. Results 86 patients with advanced gastric and colorectal cancer patients and 52.3% total efficiency, tumor control rate（CR＋PR＋SD） was 74.4%, most of the patients to alleviate symptoms of subjective feeling, improved quality of life, slight toxicity, the most patients could tolerate the treatment. Conclusion Xeloda combined with oxaliplatin as first--line regimen in the treatment of gastric cancer and colorectal cancer the precise effect of the recent and significantly improve the clinical symptoms, low toxicity, and the treatment can be tolerated.
